Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Open-label, Comparative Safety and Efficacy Study of Tipranavir Boosted With Low-dose Ritonavir (TPV/RTV) Verses Genotypically-defined Protease Inhibitor/Ritonavir (PI/RTV) in Multiple Antiretroviral Drug-experienced Patients.

NCT00054717 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT00054717
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00054717 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Open-label, Comparative Safety and Efficacy Study of Tipranavir Boosted With Low-dose Ritonavir (TPV/RTV) Verses Genotypically-defined Protease Inhibitor/Ritonavir (PI/RTV) in Multiple Antiretroviral Drug-experienced Patients.
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2003
Completion date
Not reported
Enrollment
630 (actual)
Sites
117

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections